AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD
The drug has already been approved for this indication in the EU, with regulatory reviews continuing elsewhere including in the US
Read More
Tag: NMOSD
Roche’s Enspryng approved for Neuromyelitis Optica Spectrum Disorder
Enspryng is the first approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology
Read More
EU expands approval of Alexion’s Soliris
At 48 weeks, 98% of patients treated with the drug were relapse free compared to 63% of patients receiving placebo.
Read More
AZ’ neuromyelitis drug picks up Orphan status in EU
European regulators have awarded AstraZeneca’s inebilizumab (formerly MEDI-551) Orphan status for the treatment of neuromyelitis optica spectrum disorder (NMOSD), opening the door to certain development and market exclusivity benefits.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
